Change Management for Virtual Pharmaceutical Firms. Randall Tlachac Molecular and Cellular Therapeutics



Similar documents
Guidance for Industry. Q10 Pharmaceutical Quality System

Risk Based Pre-Approval Inspection

Annex 7 Guidelines on pre-approval inspections

Guidance for Industry

PHARMACEUTICAL QUALITY SYSTEM Q10

Addressing Risk in Partner / Contractor Selection and Onboarding. Michael Davidson VP Quality Systems and Compliance March 2014

TrackWise - Quality Management System

Guidance for Industry: Starting Material Supplier Management

Pharmaceutical Quality Systems: US Perspective

Tapping the benefits of business analytics and optimization

Optimizing Quality Control / Quality Assurance Agents of a Global Sourcing / Procurement Strategy

Quality by Design Concept

ICH guideline Q10 on pharmaceutical quality system

Software Validation in Clinical Trial Reporting: Experiences from the Biostatistical & Data Sciences Department

QbD Considerations for Analytical Methods - FDA Perspective

Comparison between FDA QSR and ISO 13485

Best Practice In A Change Management System

ICH Q10 Pharmaceutical Quality System (PQS)

Application of Quality Risk Management to Pharmaceutical Operations. Eldon Henson, Vice President, Quality Operations

Title:: Effective GMP AUDITS for APIs and Formulation Pharma Companies By G.Sundar-Director/Consultant PharmQA Compliance solutions

Quality Metrics An FDA Perspective PDA Dinner and Dialogue. Melissa Seymour VP, Corporate Quality DRAFT

South African Green Drop Certification for Excellence in Wastewater Treatment Plant Operation

ENTERPRISE PROJECT MANAGEMENT OFFICE

ICH Q 10 Pharmaceutical Quality System PQS DIA China Annual Meeting, May 2010

QUALITY RISK MANAGEMENT (QRM): A REVIEW

ICH Q10 - Pharmaceutical Quality System

ORACLE CONSULTING GROUP

TRAINING TITLE: CAPA System Expert Certification (CERT-003)

QSIT Management Controls. QSIT Workshops

Guidance for Industry Quality Systems Approach to Pharmaceutical CGMP Regulations

COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS

ICH guideline Q8, Q9 and Q10 - questions and answers volume 4

Quality Agreement. by and between. Supplier Name. Address: and. Client Name: Address:

Guidance for Industry Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products

Guidance for Industry and FDA Staff: Current Good Manufacturing Practice Requirements for Combination Products

Adopting Site Quality Management to Optimize Risk-Based Monitoring

Pharmaceutical Quality Management System: Current Concept

An FDA Perspective on Post- Approval Change Management for PAT and RTRT

IVD Regulation Overview. Requirements to Assure Quality & Effectiveness

Table of Contents. Presented by

Enterprise Information Management for the Food and Beverage Industry

GRADUATE CERTIFICATE IN GOOD MANUFACTURING PRACTICE (GMP) Plan your career for tomorrow and you will be ahead of your competitors

Imperative. Tim Mohn Industry Principal Sparta Systems

Michael Kickuth and Thomas Friedli

Preparing for the Pre-Approval Inspection What to do Before the FDA Arrives. Barry A. Friedman, Ph.D. Consultant

2014 Annual FDA Medical Device Quality System Data. FDA Form 483 Observations and Warning Letter Citations

ASSESSMENT OF QUALITY RISK MANAGEMENT IMPLEMENTATION

Auditing as a Component of a Pharmaceutical Quality System

BUILDING QUALITY INTO CLINICAL TRIALS AN FDA PERSPECTIVE

Establish Collaborative Strategies to Better Manage a Global Vendor Network Devise a Proper Float Plan

Quality Considerations for Breakthrough Therapies-FDA Perspective

Conducting a Gap Analysis on your Change Control System. Presented By Miguel Montalvo, President, Expert Validation Consulting, Inc.

Quality by Design Approaches to Analytical Methods -- FDA Perspective. Yubing Tang, Ph.D. FDA/CDER/ONDQA AAPS, Washington DC October 25, 2011

Library Guide: Pharmaceutical GMPs

FDA STAFF MANUAL GUIDES, VOLUME I - ORGANIZATIONS AND FUNCTIONS FOOD AND DRUG ADMINISTRATION OFFICE OF GLOBAL AND REGULATORY OPERATIONS AND POLICY

Data Center Consolidation

ISO 14001:2015 How your ISO audit will be different. Whitepaper

Virtual Firms and Outsourcing Why the Project Management Model May Represent the Best Option By Christopher Kulp and Linda Tedeschi Miller

CAPA - the importance of data analysis

Quality by Design (QbD) Overview

LEADERSHIP STYLES. This chapter describes the difference between traditional leadership and collaborative leadership. A Traditional Leader

Introduction to Q10 Pharmaceutical Quality System

State of Control Over the Lifecycle and Process Validation (New and Legacy Products)

Outsourcing Rigor FIVE STEPS FOR IMPLEMENTING OUTSOURCING ENGAGEMENTS IN HIGHLY REGULATED ENVIRONMENTS MICHAEL KOPER AND JUAN LUEVANO

Multivariate Tools for Modern Pharmaceutical Control FDA Perspective

Standard of measurement by which efficiency, performance, progress, or quality of a plan, process, or product can be assessed 1.

[ABOUT THE AUTHOR. FDA Lifecycle Approach to Process Validation What, Why, and How? PQ Forum. Paul L. Pluta]


Validating Methods using Waters Empower TM 2 Method. Validation. Manager

Consumer Goods and Services

Aligning Quality Management Processes to Compliance Goals

Eagle Machining, Inc. Quality Management System

Good Manufacturing Practices: A Synopsis of Their Role and Rationale in Today's Pharmaceutical Marketplace for Tubing


Document Control Management System

Guidance for Industry PAT A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance

The Effective Management of Change Across the ICHQ10 Lifecycle

Moving from Quality Control to Quality Assurance (Proactive Compliance!)

Guidance for Industry

Table of Contents. Preface 1.0 Introduction 2.0 Scope 3.0 Purpose 4.0 Rationale 5.0 References 6.0 Definitions

BIOTECHNOLOGY OPERATIONS

Lifecycle CMC Management: ICH Q12 Progress to date

Safety and Health Management Systems Assessments

Accenture Accelerated R&D Services:

Enterprise Level Change Control: A Life Science Business Imperative. Presented by: Carl Ning Solutions Delivery Manager Sparta Systems

Corrective and Preventive Actions

The FDA recently announced a significant

CITY OF VAUGHAN EXTRACT FROM COUNCIL MEETING MINUTES OF FEBRUARY 17, 2015

The Ever-increasing Complexity of Biotech Changes - A Pledge for Global Convergence

Guidance for Industry

7 Steps to Healthcare Strategic Planning

Regulatory Expectations of Executive Management

Employee Performance Review

TIER II STANDARD FOR AUDITORS

The Management System Track

Risk-Based Change Management Using QbD Principles

COTS Validation Post FDA & Other Regulations

Transcription:

Change Management for Virtual Pharmaceutical Firms Randall Tlachac Molecular and Cellular Therapeutics

Opening Considerations Managing the kinds of changes encountered by and instituted between two organizations requires an unusually broad and finely honed set of skills, including: Empathy Clarity Communication Responsiveness Detailed planning and analysis

The Perspective of a Virtual Firm

Purpose Meaning of Change Management for Virtual Firms Unique Challenges Quality and Manufacturing Agreements Document Systems Outcomes of Effective Change Management

Meaning of Change Management Task of Managing Change and the RELATIONSHIP Process of Risk Evaluation/Assessment Definition of the level and detail and information Procedures and mechanisms for effectively managing change

Meaning of Change Management Defining the Systems at both firms Focusing on relationship building Enabling change in a risk-based manner Managing the change process Allowing for Innovation, Process Improvement and Optimization Assuring Quality by Design

What are unique challenges to Virtual Firms? Need to manage at least two Quality Systems Changes to be managed lie within and are NOT controlled by your organization Identify the interfaces Identify differences Impact on CMC sections Each firm sees risk in a different way

Manage the Interface Clearly understand the interface Prepare a Process Map for processes, inputs and outputs, meet and discuss Early on, focus on the point at which both organizations truly interact Encourage performance Identify and eliminate obstacles

What are unique challenges to Virtual Firms? Determine if anticipative and proactive or knee jerk and reactive Different processes for regulatory interpretations Master Parallel Review Cycles Encourage and motivate supplier to improve and optimize

Is your firm proactive or reactive How you approach depends on - Examine capabilities of your firm from a process, production, technical, quality, regulatory knowledge-based perspective What is your style Can you rely on the CMO/CRO to make major decisions about your product

Parallel Review Cycles Try to achieve efficient parallel reviews at both firms Attempt to incorporate this parallel review in one process Try to achieve equivalent risk assessment mechanisms

Encourage and motivate supplier to improve and optimize Change Control systems should be DYNAMIC ENABLERS for optimization Find ways and establish relationships with operators and analysts to encourage understanding and participation with the Change Control Process Identify and avoid the potential for disincentives for change

Different processes for regulatory interpretations Examine carefully the philosophy and process for the CMO/CRO interpretations Ensure that you have agreement on how changes are interpreted Ask specific questions regarding process, method and procedural changes and how they are processed Agreeing on the defined set of Controlled Documents subject to your review can help

Quality Agreements The Basics AT THE EARLIEST STAGE - Start with a comprehensive Quality Agreement Basis of information, who provides what Identify points of control Identify responsibilities Documentation Change Control and Risk Management Discuss Deviations and OOS situations Use to tightly bind your suppliers to you

Quality Agreements Key Elements Maintain involvement and understanding Define changes the manufacturer may make, using Risk Management Processes, to improve or implement changes Identify raw material, component, process and product controls within the design space to create requirements or guideline against which change management, risk assessment, and audits may be performed Periodic on-site reviews to evaluate deviations, CAPA, outcomes of joint actions Provisions for assessment of manufacturing issues related to Adverse Experiences

Quality Agreements What If? Regardless of the details in the Quality Agreement, the culture of the organizations and the relationship you have developed will make a difference when problems arise

Manufacturing and Supply Agreements Build in flexibility and provide accommodations for improvements Understand variability in raw materials and processing Regional Regulatory Approaches Constantly assess changes in interactions for improvement Agreements should be DYNAMIC

Integrate Document Change Control as part of Regulatory Process Choose team members with relevant skills and high energy levels Ensure that provisions are in place for evaluation of changes for regulatory impact for both parties Agree on timelines and expectations for evaluation and risk assessment Be prepared to Get to Know Your PARTNER

Document Systems Determine in which documentation system the CMC will reside Transfer the CMC in its entirety Provide Summary Document Transfer Manufacturing, Quality Control Methods, Specifications in your document format

Documents to Consider Full CMC Amendments Annual Reports Product, In-Process, Drug Substance Specifications Analytical Methods Master Batch Records Inspection Procedures Sampling Procedures and Requirements Certificates of Analysis and/or Compliance

Document Systems Establish distribution system List of documents maintained per Quality Agreement Maintain jointly a list revisions currently in effect Insist on formal acknowledgement of distributed documents

Document Systems Determine if philosophies for change evaluation are compatible Ensure and commit to a rapid review process for all proposed changes Seek compatible approach in level and detail of information

Outcomes of Effective Change Management for Virtual Firms Vision and plan for achieving change Implementation of an communications plan Established standard for performance (from meeting times for participants to turnaround for change) Built an effective team Awards and incentives

Outcomes of Effective Change Management for Virtual Firms CMOs/CROs will prefer to work with you Reduce time to approval and market An additional team will be helping you solve your problems Effective Change Management SHOWS and gives FDA confidence in the team during the PAI process

Outcomes of Effective Change Management for Virtual Firms Demand and Nurture Progress Able to maintain aggressive schedules Maintain momentum Identify interdependencies Facilitate enterprise wide involvement Continue to realign competencies in the groups to support the model

Connecting the Dots Seek to understand Be clear Adapt, control and effect change Make it look easy

Change as a What Problem What are we trying to accomplish? What changes are necessary? What are measures of success? What standards apply? What are the periodic measures of performance? Ask Why questions to get at the heart of improving interactions.

Selected Sources 1. Strategic Organizational Change - Michael Beitler 1. The Planning of Change - Warren Bettis 2. Organizations in Action - James D. Thompson

Contact Information Randall Tlachac Molecular and Cellular Therapeutics University of Minnesota (612) 624-0765 rtlachac@umn.edu